Cargando…

Mirtazapine treatment of diabetic gastroparesis as a novel method to reduce tube-feed residual: a case report

INTRODUCTION: Gastroparesis is a common motility disorder that is characterized by delayed gastric emptying in the absence of mechanical obstruction. Diabetes, along with other neuromuscular and infiltrating disorders, can predispose individuals to an increased risk of developing gastroparesis. Gast...

Descripción completa

Detalles Bibliográficos
Autores principales: Gooden, Janelle Y, Takahashi, Paul Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570274/
https://www.ncbi.nlm.nih.gov/pubmed/23388206
http://dx.doi.org/10.1186/1752-1947-7-38
_version_ 1782259035777531904
author Gooden, Janelle Y
Takahashi, Paul Y
author_facet Gooden, Janelle Y
Takahashi, Paul Y
author_sort Gooden, Janelle Y
collection PubMed
description INTRODUCTION: Gastroparesis is a common motility disorder that is characterized by delayed gastric emptying in the absence of mechanical obstruction. Diabetes, along with other neuromuscular and infiltrating disorders, can predispose individuals to an increased risk of developing gastroparesis. Gastroparesis can be easily diagnosed through gastric emptying studies but is usually difficult to successfully treat. Therapy usually begins with pro-kinetic and anti-emetic agents. CASE PRESENTATION: Our patient was an 87-year-old African-American woman who was a nursing home resident, with a history of diabetes mellitus type 2 and subarachnoid hemorrhage leading to aphasia, hemiplegia, seizures and dysphagia requiring percutaneous gastric feeds. While at the nursing home, she had recurrent aspiration pneumonia and large tube-feed residuals consistent with a diagnosis of underlying gastroparesis. Her management included metoclopramide and reduced tube-feeding rates, which improved her symptoms. However, within months the aspiration and increased residuals returned. After trials of different medication therapies without success, she started mirtazapine and her residual volume and aspirations decreased with a dose of 15mg nightly. CONCLUSION: In patients with gastroparesis recalcitrant to first line therapies such as metoclopramide, off-label use of mirtazapine may provide adequate non-invasive management of gastroparetic symptoms.
format Online
Article
Text
id pubmed-3570274
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35702742013-02-13 Mirtazapine treatment of diabetic gastroparesis as a novel method to reduce tube-feed residual: a case report Gooden, Janelle Y Takahashi, Paul Y J Med Case Rep Case Report INTRODUCTION: Gastroparesis is a common motility disorder that is characterized by delayed gastric emptying in the absence of mechanical obstruction. Diabetes, along with other neuromuscular and infiltrating disorders, can predispose individuals to an increased risk of developing gastroparesis. Gastroparesis can be easily diagnosed through gastric emptying studies but is usually difficult to successfully treat. Therapy usually begins with pro-kinetic and anti-emetic agents. CASE PRESENTATION: Our patient was an 87-year-old African-American woman who was a nursing home resident, with a history of diabetes mellitus type 2 and subarachnoid hemorrhage leading to aphasia, hemiplegia, seizures and dysphagia requiring percutaneous gastric feeds. While at the nursing home, she had recurrent aspiration pneumonia and large tube-feed residuals consistent with a diagnosis of underlying gastroparesis. Her management included metoclopramide and reduced tube-feeding rates, which improved her symptoms. However, within months the aspiration and increased residuals returned. After trials of different medication therapies without success, she started mirtazapine and her residual volume and aspirations decreased with a dose of 15mg nightly. CONCLUSION: In patients with gastroparesis recalcitrant to first line therapies such as metoclopramide, off-label use of mirtazapine may provide adequate non-invasive management of gastroparetic symptoms. BioMed Central 2013-02-06 /pmc/articles/PMC3570274/ /pubmed/23388206 http://dx.doi.org/10.1186/1752-1947-7-38 Text en Copyright ©2013 Gooden and Takahashi; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Gooden, Janelle Y
Takahashi, Paul Y
Mirtazapine treatment of diabetic gastroparesis as a novel method to reduce tube-feed residual: a case report
title Mirtazapine treatment of diabetic gastroparesis as a novel method to reduce tube-feed residual: a case report
title_full Mirtazapine treatment of diabetic gastroparesis as a novel method to reduce tube-feed residual: a case report
title_fullStr Mirtazapine treatment of diabetic gastroparesis as a novel method to reduce tube-feed residual: a case report
title_full_unstemmed Mirtazapine treatment of diabetic gastroparesis as a novel method to reduce tube-feed residual: a case report
title_short Mirtazapine treatment of diabetic gastroparesis as a novel method to reduce tube-feed residual: a case report
title_sort mirtazapine treatment of diabetic gastroparesis as a novel method to reduce tube-feed residual: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570274/
https://www.ncbi.nlm.nih.gov/pubmed/23388206
http://dx.doi.org/10.1186/1752-1947-7-38
work_keys_str_mv AT goodenjanelley mirtazapinetreatmentofdiabeticgastroparesisasanovelmethodtoreducetubefeedresidualacasereport
AT takahashipauly mirtazapinetreatmentofdiabeticgastroparesisasanovelmethodtoreducetubefeedresidualacasereport